The University of Chicago Header Logo

Connection

Peter Sand to Severity of Illness Index

This is a "connection" page, showing publications Peter Sand has written about Severity of Illness Index.
Connection Strength

0.421
  1. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013 Sep; 190(3):958-64.
    View in: PubMed
    Score: 0.071
  2. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. 2009; 27(4):329-39.
    View in: PubMed
    Score: 0.054
  3. Predictors of persistent detrusor overactivity after transvaginal sling procedures. Am J Obstet Gynecol. 2008 Dec; 199(6):696.e1-7.
    View in: PubMed
    Score: 0.053
  4. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007 Apr; 99(4):836-44.
    View in: PubMed
    Score: 0.047
  5. Do alterations in vaginal dimensions after reconstructive pelvic surgeries affect the risk for dyspareunia? Am J Obstet Gynecol. 2005 May; 192(5):1573-7.
    View in: PubMed
    Score: 0.042
  6. Site-specific rectocele repair compared with standard posterior colporrhaphy. Obstet Gynecol. 2005 Feb; 105(2):314-8.
    View in: PubMed
    Score: 0.041
  7. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004 Jul-Aug; 15(4):243-8.
    View in: PubMed
    Score: 0.039
  8. A randomized controlled trial comparing a modified Burch procedure and a suburethral sling: long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Oct; 14(4):229-33; discussion 233.
    View in: PubMed
    Score: 0.037
  9. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013 Jun; 189(6):2186-93.
    View in: PubMed
    Score: 0.018
  10. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007 Dec; 178(6):2488-94.
    View in: PubMed
    Score: 0.012
  11. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001 Apr; 76(4):358-63.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.